(Q50569982)

English

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.

scientific article published in December 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. (English)

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

object named as

Sanaa M Kamal

1

0 references

Michelle D Shardell

3

object named as

Michelle D Shardell

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

author name string

Samer S El Kamary

2

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

Mohamed Hashem

4

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

Imad N Ahmed

5

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

Mohamed Muhammadi

6

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

Khalifa Sayed

7

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

Ashraf Moustafa

8

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

Sarah Abdel Hakem

9

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

Amany Ibrahiem

10

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

Mohamed Moniem

11

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

Hoda Mansour

12

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

Mohamed Abdelaziz

13

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

language of work or name

0 references

publication date

1 December 2007

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

46

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

1732-1740

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

6

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

21 January 2018

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

21 January 2018

Genetic epidemiology of hepatitis C virus throughout egypt

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Infection with hepatitis C virus genotype 4 in the United States

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon therapy in patients with chronic hepatitis C and schistosomiasis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

"Proving the null hypothesis" in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic hepatitis C therapy: changing the rules of duration

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21917

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.21917

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/17943989

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50569982&oldid=2075491734"